ADVance - Adenoviruses as novel clinical treatments.
Operm positions for early stage researchers (ESR - i.e. PhD fellows) and experienced researchers (ER - i.e. post-doc)
Starting on 1st April 2012.
Closing date for applications 15th March 2012
Fri, 11/11/2011
University of Glasgow
College of Medical, Veterinary & Life Sciences
Institute of Cardiovascular and Medical Sciences
Professor / Reader / Senior Lecturer in Translational Cardiovascular Science (non clinical)
Ref: M00380
Salary: Senior Lecturer / Reader: £46,596 – £52,556
Professor: £ Negotiable
The Institute of Cardiovascular and Medical Sciences invite applications for this new post which forms an essential part of a strategic expansion of cardiovascular research in the University. Applications from non-clinical cardiovascular researchers are welcome.
The main purpose of this post will be to advance Translational Cardiovascular research in the University of Glasgow. The scientific focus is within the areas of vascular biology, gene therapy, MiRNA therapeutics, vascular stem cell biology, with the main criteria being research excellence and leadership potential.
The appointee will be based in the Institute of Cardiovascular & Medical Science within the British Heart Foundation Glasgow Cardiovascular Research Centre (BHF GCRC), a purpose built research centre consolidating under one roof internationally recognised cardiovascular research groups in the University Further information on the centre is available at:
http://www.gla.ac.uk/researchinstitutes/icams/aboutus/ourfacilities/bhfgcrc/
Level of appointment will be dependent upon experience and informal enquiries may be made to:
Professor A Baker, Director, Institute of Cardiovascular and Medical Sciences
E-mail: Andrew.H.Baker@glasgow.ac.uk
Apply online at www.glasgow.ac.uk/jobs
Closing date: 11th Nov 2011.
The University is committed to equality of opportunity in employment.
The University of Glasgow, charity number SC004401.
Sat, 01/10/2011
EVBO and ESM have agreed to hold a joint meeting under the auspices of the International Union of Physiological Sciences (IUPS) Conference, hosted by the UK Physiological Society in Birmingham from 21st-26th July 2013.
To ensure the best possible representation of vascular biology and microcirculation symposia at IUPS, you are invited to submit pre-proposals online for the symposia by 1 October, which will be screened by a joint EVBO/ESM committee, and ranked and merged to form a balanced set of around 25 symposia. The time scale is short, even though the conference is over 20 months away, because of the need to liaise with the IUPS programe committee. Note that you do not need to contact the proposed chair/speakers before submission - we simply want your help to design a programme with the best possible science.
To submit your proposal go to:
http://www.microcirculation.org.uk/27esm7evbo/index.html
Fri, 24/06/2011
Research Associate – Vascular Biology/
Gene Therapy
Grade 7: £31,798 - £35,788 per annum Ref: M00279
This post is available in the group led by Professor Andrew Baker as part
of a British Heart Foundation programme grant. Experience in vascular
biology/virology/gene therapy or microRNA is an advantage.
Informal enquiries to Prof Baker, 0141 330 1977 email:
Funding for this post is available for three years and six months.
Apply online at www.glasgow.ac.uk/jobs
Thu, 18/11/2010
A British Heart Foundation (BHF) PhD studentship (3 years) is now available in the Prof Emanueli laboratory of Vascular Pathology and Regeneration at the University of Bristol.
The research project is entitled "Role of miRNA-30c2* in diabetes-induced impairment of post-ischaemic neovascularisation in limb muscles".
Fri, 01/10/2010
Attached is a PDF flyer with an opening for a postdoctoral scientist in Professor Helmut Augustin's laboratory at the German Cancer Research Center (DKFZ) in Heidelberg. This position is available for outstandingly talented and motivated candidates interested in pursuing postdoctoral training in the fields of angiogenesis and/or tumor biology. This is a unique opportunity in one of the most exciting fields of contemporary life science research.
DKFZ is a great place to work at and Heidelberg is a wonderful city to live in. Our lab is run according to work hard / play hard principles, i.e., we take our mission extremely serious, but we are also balanced people with a great team spirit in the lab.
I am looking forward to hearing from interested candidates.
Best wishes, Hellmut Augustin
Hellmut G. Augustin, DVM, PhD
Professor and Director
Aventis Foundation-endowed Chair for Vascular Biology and Tumor Angiogenesis
Medical Faculty Mannheim, Heidelberg University, and
German Cancer Research Center Heidelberg (DKFZ)
HD lab: DKFZ, Im Neuenheimer Feld 280, D-69120 Heidelberg
MA lab: CBTM, Ludolph-Krehl-Str. 13-17, D-68167 Mannheim
Tel: +49-(0)6221-42-1500; +49-(0)621-383-9960
Web: www.angiolab.de; Email: augustin@angiogenese.de
Sun, 01/08/2010
Two positions (Post-docs and PhD student) are currently available funded in part by the Italian
Association of Cancer Research (AIRC) and Human Frontiers Science Program (HFSP) to work at the Molecular Biotechnology Center, University of Torino (Italy). Please visit our website
www.mbcunito.it
for more informations.
The research activities will be focused on:
1) Characterization of new molecular pathways involved in pathological angiogenesis.
2) Role of vascular mural stem cells biology in tissue regeneration in zebrafish. Massimo M. Santoro, PhD
Molecular Biotechnology Center
University of Torino, Via Nizza, 52
10126 Torino, ITALY
Phone: +39 011 6706499
email: massimo.santoro@unito.it
Molecular Massimo M. Santoro, PhD
Journal of Natural Science, Biology and Medicine (J Nat Sc Biol Med) www.jnsbm.org – An official publication of Society of Science, Biology and Medicine (www.scibiolmed.org) – is calling for papers for a mini series targeting on “angiogenesis” for the next issue. All types of articles are considered including Research articles, Review articles, Letters to editor, Brief communications, Case reports, Book reviews, Technological reports, and Opinion articles. While submitting articles please mention 'mini series on angiogenesis' on the first page of the manuscript. Manuscripts in this category will be processed for quick review shortly after submission and prioritized for publication. Detailed instructions for submitting manuscripts can be found at www.jnsbm.org.
We are looking for a highly motivated postdoctoral scientist to join the "Signaling and Hypertension" team that investigates the role of Rho proteins in vascular smooth muscle cells and their involvement in arterial diseases.
The research project will focus on the characterization of the role of the Rho protein Rac1 in the cardiovascular system, in arterial smooth muscle and endothelial cells. Both cell and animal models will be used to perform gene/function analyses by several approaches including molecular biology, biochemistry, cell biology and functional studies.
The successful applicant should have a PhD in biochemistry/cell biology and physiology/molecular biology with strong motivation and interest in cell signaling.
Ideal candidates will have good skills in biochemistry (protein extraction, western blot, immunoprecipitation), in molecular and cellular biology, transfection and cell culture. Experience in physiology (animal experimentation) and in cardiovascular area will be an advantage.
Interested applicants should submit a CV (which lists at least 2 references) and a brief letter (1 page) outlining prior research experience and personal research interests.
Contact: Vincent SAUZEAU
Phone: +33-2 28 08 01 75
e-mail: vincent.sauzeau@inserm.fr
Main recent publications:
1- Loirand G, Pacaud P. The role of Rho protein signaling in hypertension. Nat Rev Cardiol. 2010 Nov;7(11):637-47.
2- Sauzeau V, Berenjeno IM, Citterio C, Bustelo XR. A transcriptional cross-talk between RhoA and c-Myc inhibits the RhoA/Rock-dependent cytoskeleton. Oncogene. 2010.
3- Guilluy C, Brégeon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, Loufrani L, Henrion D, Scalbert E, Bril A, Torres RM, Offermanns S, Pacaud P, Loirand G. The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure. Nat Med. 2010 Feb;16(2):183-90.
4- Sauzeau V, Sevilla MA, Montero MJ, Bustelo XR. The Rho/Rac exchange factor Vav2 controls nitric oxide-dependent responses in mouse vascular smooth muscle cells. J Clin Invest. 2010 Jan;120(1):315-30.
5- Sauzeau V, Jerkic M, López-Novoa JM, Bustelo XR. Loss of Vav2 proto-oncogene causes tachycardia and cardiovascular disease in mice. Mol Biol Cell. 2007 Mar;18(3):943-52
6- Sauzeau V, Sevilla MA, Rivas-Elena JV, de Alava E, Montero MJ, López-Novoa JM, Bustelo XR. Vav3 proto-oncogene deficiency leads to sympathetic hyperactivity and cardiovascular dysfunction. Nat Med. 2006 Jul;12(7):841-5.